Bone Research Development from 2010 to 2026
| BBLG Stock | USD 1.64 0.04 2.38% |
Research Development | First Reported 2013-03-31 | Previous Quarter 191.6 K | Current Value 187.8 K | Quarterly Volatility 1 M |
Check Bone Biologics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Bone Biologics' main balance sheet or income statement drivers, such as Other Operating Expenses of 4.1 M, Ebitda of 101.3 K or Total Operating Expenses of 4.7 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.3 or PTB Ratio of 2.32. Bone financial statements analysis is a perfect complement when working with Bone Biologics Valuation or Volatility modules.
Bone | Research Development | Build AI portfolio with Bone Stock |
The Research Development trend for Bone Biologics Corp offers valuable insights into the company's financial trajectory and strategic direction. By examining multi-year patterns, investors can identify whether Bone Biologics is strengthening or weakening its position, and how this metric correlates with broader market conditions and industry benchmarks.
Latest Bone Biologics' Research Development Growth Pattern
Below is the plot of the Research Development of Bone Biologics Corp over the last few years. It is Bone Biologics' Research Development historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Bone Biologics' overall financial position and show how it may be relating to other accounts over time.
| Research Development | 10 Years Trend |
|
Research Development |
| Timeline |
Bone Research Development Regression Statistics
| Arithmetic Mean | 2,027,155 | |
| Geometric Mean | 246,318 | |
| Coefficient Of Variation | 150.22 | |
| Mean Deviation | 2,010,698 | |
| Median | 1,095,176 | |
| Standard Deviation | 3,045,288 | |
| Sample Variance | 9.3T | |
| Range | 11.6M | |
| R-Value | 0.22 | |
| Mean Square Error | 9.4T | |
| R-Squared | 0.05 | |
| Significance | 0.40 | |
| Slope | 132,223 | |
| Total Sum of Squares | 148.4T |
Bone Research Development History
About Bone Biologics Financial Statements
Bone Biologics stakeholders use historical fundamental indicators, such as Bone Biologics' Research Development, to determine how well the company is positioned to perform in the future. Although Bone Biologics investors may analyze each financial statement separately, they are all interrelated. For example, changes in Bone Biologics' assets and liabilities are reflected in the revenues and expenses on Bone Biologics' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Bone Biologics Corp. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Research Development | 2.4 M | 2.5 M |
Currently Active Assets on Macroaxis
When determining whether Bone Biologics Corp is a strong investment it is important to analyze Bone Biologics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Bone Biologics' future performance. For an informed investment choice regarding Bone Stock, refer to the following important reports:Check out the analysis of Bone Biologics Correlation against competitors. You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.
Can Health Care Equipment & Supplies industry sustain growth momentum? Does Bone have expansion opportunities? Factors like these will boost the valuation of Bone Biologics. Projected growth potential of Bone fundamentally drives upward valuation adjustments. Determining accurate worth demands scrutiny of both present operating results and projected expansion capacity. Evaluating Bone Biologics demands reviewing these metrics collectively while recognizing certain factors exert disproportionate influence.
The market value of Bone Biologics Corp is measured differently than its book value, which is the value of Bone that is recorded on the company's balance sheet. Investors also form their own opinion of Bone Biologics' value that differs from its market value or its book value, called intrinsic value, which is Bone Biologics' true underlying value. Market participants employ diverse analytical approaches to determine fair value and identify buying opportunities when prices dip below calculated worth. Because Bone Biologics' market value can be influenced by many factors that don't directly affect Bone Biologics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between Bone Biologics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Bone Biologics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Bone Biologics' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.